Swedish Drugmaker Meda Said to Weigh Sale of U.S. OperationsBy and
Rothschild is advising Meda; sale may start in September
Company may fetch about $1 billion from sale of U.S business
Swedish drugmaker Meda AB is exploring options including a sale of its U.S. operations amid a boom in health care deals, according to people with knowledge of the matter. The company’s shares jumped in Stockholm.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.